Profile
Dr. James Clark is Vice President-Clinical Laboratory Operations at Inivata Ltd.
and Chief Technology Officer at Enterome SA.
Dr. Clark was previously employed as Chief Operating Officer & Vice President by Response Genetics, Inc., Head-Technology Group by GlaxoSmithKline Biologicals SA, and Vice President-Research & Development by MDxHealth SA.
He received his undergraduate degree from Heriot-Watt University and a doctorate degree from the University of Glasgow.
James Clark active positions
| Companies | Position | Start |
|---|
Former positions of James Clark
| Companies | Position | End |
|---|---|---|
| RESPONSE GENETICS, INC | Chief Operating Officer | 08/02/2009 |
Inivata Ltd.
 Inivata Ltd. Packaged SoftwareTechnology Services Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - |
GlaxoSmithKline Biologicals NV
 GlaxoSmithKline Biologicals NV BiotechnologyHealth Technology GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium. | Chief Tech/Sci/R&D Officer | - |
Enterome SA
 Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France. | Chief Tech/Sci/R&D Officer | - |
| MDXHEALTH SA | Chief Tech/Sci/R&D Officer | - |
Training of James Clark
| Heriot-Watt University | Undergraduate Degree |
| University of Glasgow | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| RESPONSE GENETICS, INC | Health Technology |
| MDXHEALTH SA | Health Technology |
| Private companies | 3 |
|---|---|
Enterome SA
Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France. | Health Technology |
GlaxoSmithKline Biologicals NV
GlaxoSmithKline Biologicals NV BiotechnologyHealth Technology GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium. | Health Technology |
Inivata Ltd.
Inivata Ltd. Packaged SoftwareTechnology Services Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom. | Technology Services |
- Stock Market
- Insiders
- James Clark
